BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …

The discovery of activating mutations in the serine/threonine (S/T) kinase BRAF followed by
a wave of follow-up research manifested that the MAPK-pathway plays a critical role in …

The discovery of activating BRAF mutations in melanomas has led to the investigation of
small molecular inhibitors targeting BRAF mutation and MEK, a downstream protein within …

Opinion statement Melanoma is caused by a variety of somatic mutations, and among these
mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a …

Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …

The discovery of activating BRAF mutations in∼ 50% of all melanomas has proved to be a
turning point in the therapeutic management of the disseminated disease. In this …

The efficacy of selective BRAF inhibitors has now been established in the 50% of patients
with metastatic melanoma whose tumors harbor activating mutations. However, for the vast …

Mitogen-activated protein kinase (MAPK) pathway has an important role in normal cells and
can be activated under physiological conditions. MAPK pathway activation is a fundamental …

The mitogen-activated protein kinase (MAPK) pathway has emerged as a central target for
melanoma therapy due to its persistent activation in the majority of tumors. Several BRAF …

The discovery of BRAF mutations in melanoma has not yet translated into clinical success,
suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the …